Matches in SemOpenAlex for { <https://semopenalex.org/work/W2103079055> ?p ?o ?g. }
- W2103079055 endingPage "956" @default.
- W2103079055 startingPage "949" @default.
- W2103079055 abstract "Diffuse-type tenosynovial giant cell tumour (dt-GCT) of the soft tissue (alternatively known as pigmented villonodular synovitis), an orphan disease with unmet medical need, is characterised by an overexpression of colony-stimulating factor 1 (CSF1), and is usually caused by a chromosomal translocation involving CSF1. CSF1 receptor (CSF1R) activation leads to the recruitment of CSF1R-expressing cells of the mononuclear phagocyte lineage that constitute the tumor mass in dt-GCT. Emactuzumab (RG7155) is a novel monoclonal antibody that inhibits CSF1R activation. We have assessed the safety, tolerability and activity of emactuzumab in patients with Dt-GCT of the soft tissue.In this phase 1, first-in-human dose-escalation and dose-expansion study, eligible patients were aged 18 years or older with dt-GCT of the soft tissue with locally advanced disease or resectable tumours requiring extensive surgery, an Eastern Cooperative Oncology Group performance status of 1 or less, measurable disease according to Response Evaluation Criteria In Solid Tumors version 1.1, and adequate end-organ function. Patients with GCT of the bone were not eligible. Patients received intravenous emactuzumab at 900 mg, 1350 mg, or 2000 mg every 2 weeks in the dose-escalation phase and at the optimal biological dose in a dose-expansion phase. The primary objective was to evaluate the safety and tolerability of emactuzumab, and to determine the maximum tolerated dose or optimal biological dose. All treated patients were included in the analyses. Expansion cohorts are currently ongoing. This study is registered with ClinicalTrials.gov, number NCT01494688.Between July 26, 2012, and Oct 21, 2013, 12 patients were enrolled in the dose-escalation phase. No dose-limiting toxicities were noted in the dose-escalation cohort; on the basis of pharmacokinetic, pharmacodynamic, and safety information, we chose a dose of 1000 mg every 2 week for the dose-expansion cohort, into which 17 patients were enrolled. Owing to different cutoff dates for safety and efficacy readouts, the safety population comprised 25 patients. Common adverse events after emactuzumab treatment were facial oedema (16 [64%] of 25 patients), asthenia (14 [56%]), and pruritus (14 [56%]). Five serious adverse events (periorbital oedema, lupus erythematosus [occurring twice], erythema, and dermohypodermitis all experienced by one [4%] patient each) were reported in five patients. Three of the five serious adverse events-periorbital oedema (one [4%]), lupus erythematosus (one [4%]), and dermohypodermitis (one [4%])-were assessed as grade 3. Two other grade 3 events were reported: mucositis (one [4%]) and fatigue (one [4%]). 24 (86%) of 28 patients achieved an objective response; two (7%) patients achieved a complete response.Further study of dt-GCT is warranted and different possibilities, such as an international collaboration with cooperative groups to assure appropriate recruitment in this rare disease, are currently being assessed.F Hoffmann-La Roche." @default.
- W2103079055 created "2016-06-24" @default.
- W2103079055 creator A5002046745 @default.
- W2103079055 creator A5012097701 @default.
- W2103079055 creator A5018494013 @default.
- W2103079055 creator A5023346308 @default.
- W2103079055 creator A5027371764 @default.
- W2103079055 creator A5027981275 @default.
- W2103079055 creator A5028020706 @default.
- W2103079055 creator A5028244645 @default.
- W2103079055 creator A5031346951 @default.
- W2103079055 creator A5031505278 @default.
- W2103079055 creator A5034926990 @default.
- W2103079055 creator A5042202815 @default.
- W2103079055 creator A5045020502 @default.
- W2103079055 creator A5050820747 @default.
- W2103079055 creator A5059503499 @default.
- W2103079055 creator A5060949051 @default.
- W2103079055 creator A5063649167 @default.
- W2103079055 creator A5068730563 @default.
- W2103079055 creator A5078356265 @default.
- W2103079055 creator A5078450669 @default.
- W2103079055 creator A5078496181 @default.
- W2103079055 creator A5080620486 @default.
- W2103079055 creator A5081937224 @default.
- W2103079055 creator A5082405249 @default.
- W2103079055 creator A5084836759 @default.
- W2103079055 creator A5086258188 @default.
- W2103079055 creator A5090819989 @default.
- W2103079055 date "2015-08-01" @default.
- W2103079055 modified "2023-10-17" @default.
- W2103079055 title "CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study" @default.
- W2103079055 cites W1837756289 @default.
- W2103079055 cites W1960367851 @default.
- W2103079055 cites W1964698497 @default.
- W2103079055 cites W1997499809 @default.
- W2103079055 cites W2015015957 @default.
- W2103079055 cites W2020870770 @default.
- W2103079055 cites W2034034179 @default.
- W2103079055 cites W2044532411 @default.
- W2103079055 cites W2052109465 @default.
- W2103079055 cites W2053237929 @default.
- W2103079055 cites W2076743146 @default.
- W2103079055 cites W2090004346 @default.
- W2103079055 cites W2098470178 @default.
- W2103079055 cites W2102012621 @default.
- W2103079055 cites W2107366273 @default.
- W2103079055 cites W2108549165 @default.
- W2103079055 cites W2112996193 @default.
- W2103079055 cites W2126549321 @default.
- W2103079055 cites W2136703362 @default.
- W2103079055 cites W2142901608 @default.
- W2103079055 cites W2146183809 @default.
- W2103079055 cites W2148064549 @default.
- W2103079055 cites W2149285945 @default.
- W2103079055 cites W2156758289 @default.
- W2103079055 cites W2171405465 @default.
- W2103079055 cites W2172208023 @default.
- W2103079055 doi "https://doi.org/10.1016/s1470-2045(15)00132-1" @default.
- W2103079055 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26179200" @default.
- W2103079055 hasPublicationYear "2015" @default.
- W2103079055 type Work @default.
- W2103079055 sameAs 2103079055 @default.
- W2103079055 citedByCount "277" @default.
- W2103079055 countsByYear W21030790552015 @default.
- W2103079055 countsByYear W21030790552016 @default.
- W2103079055 countsByYear W21030790552017 @default.
- W2103079055 countsByYear W21030790552018 @default.
- W2103079055 countsByYear W21030790552019 @default.
- W2103079055 countsByYear W21030790552020 @default.
- W2103079055 countsByYear W21030790552021 @default.
- W2103079055 countsByYear W21030790552022 @default.
- W2103079055 countsByYear W21030790552023 @default.
- W2103079055 crossrefType "journal-article" @default.
- W2103079055 hasAuthorship W2103079055A5002046745 @default.
- W2103079055 hasAuthorship W2103079055A5012097701 @default.
- W2103079055 hasAuthorship W2103079055A5018494013 @default.
- W2103079055 hasAuthorship W2103079055A5023346308 @default.
- W2103079055 hasAuthorship W2103079055A5027371764 @default.
- W2103079055 hasAuthorship W2103079055A5027981275 @default.
- W2103079055 hasAuthorship W2103079055A5028020706 @default.
- W2103079055 hasAuthorship W2103079055A5028244645 @default.
- W2103079055 hasAuthorship W2103079055A5031346951 @default.
- W2103079055 hasAuthorship W2103079055A5031505278 @default.
- W2103079055 hasAuthorship W2103079055A5034926990 @default.
- W2103079055 hasAuthorship W2103079055A5042202815 @default.
- W2103079055 hasAuthorship W2103079055A5045020502 @default.
- W2103079055 hasAuthorship W2103079055A5050820747 @default.
- W2103079055 hasAuthorship W2103079055A5059503499 @default.
- W2103079055 hasAuthorship W2103079055A5060949051 @default.
- W2103079055 hasAuthorship W2103079055A5063649167 @default.
- W2103079055 hasAuthorship W2103079055A5068730563 @default.
- W2103079055 hasAuthorship W2103079055A5078356265 @default.
- W2103079055 hasAuthorship W2103079055A5078450669 @default.
- W2103079055 hasAuthorship W2103079055A5078496181 @default.
- W2103079055 hasAuthorship W2103079055A5080620486 @default.
- W2103079055 hasAuthorship W2103079055A5081937224 @default.
- W2103079055 hasAuthorship W2103079055A5082405249 @default.